RyboDyn, Inc., a biotechnology company pioneering immunotherapies targeting the dark proteome, has been selected to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc. This selection provides RyboDyn with direct access to Lilly’s global scientific and business network to advance its lead programs.

Through its sequencing and AI-driven platform, RyboCypher, RyboDyn has uncovered a new class of therapeutic targets that are cancer-specific, abundantly expressed on the cell surface, and absent in healthy tissues. In collaboration with Moffitt Cancer Center, RyboDyn recently demonstrated that several of these Dark Targets are conserved across patients, supporting their potential as the foundation for first-in-class precision immunotherapies.

“We’re thrilled to join the LGL community and collaborate with peers who share our urgency to translate high-impact science,” said Imad Ajjawi, PhD, MBA, CEO and Co-founder of RyboDyn. “Lilly’s support comes at a pivotal moment as we advance our first wave of programs toward therapeutic development.”

RyboDyn’s LGL residency is part of the Lilly Catalyze360 model, which aims to empower early-stage biotech startups across all therapeutic areas by providing access to world-class lab space and drug development talent and resources through Lilly Gateway Labs, Lilly ExploR&D, and Lilly Ventures.